Clinical trials: Digestive System Malignancies
Breast Cancer, Gastric Cancer
A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)
This multicenter study will assess the maximum tolerated dose (MTD) of capecitabine in combination with Kadcyla (trastuzumab emtansine) in participants with HER2-positive mBC or HER2-positive LA/mGC using a Phase 1 design…
- Trial name
- TRAXHER2 (NCT01702558)
- Testing
- Capecitabine, Trastuzumab emtansine (T-DM1)
- Where
- 40 sites in Argentina, Brazil and 10 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Rectal Cancer
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer.
- Trial name
- NCT03259035
- Testing
- Folfox Protocol, Capox
- Where
- 11 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Canadian Cancer Trials Group
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Improving Informed Consent for Palliative Chemotherapy
Patients are routinely asked to sign an "informed consent" document prior to starting chemotherapy, indicating they understand the risks and benefits of treatment.
- Conditions
- Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
- Trial name
- NCT02282722
- Testing
- Investigational informed consent for chemotherapy, Usual, standard-of-care informed consent for chemotherapy
- Where
- 8 sites in United States
- Volunteers
- 216 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Neoplasms
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
This two-stage study is designed to compare the safety and activity between RRx-001 against regorafenib followed by irinotecan-based therapies in a parallel comparative study.
- Trial name
- ROCKET (NCT02096354)
- Testing
- RRx-001, Regorafenib, Irinotecan
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- EpicentRx, Inc.
Pancreatic Cancer
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
Gemcitabine is considered one of the standard drugs for advanced pancreatic cancer and is approved by the FDA to treat it. Cabozantinib is a new drug that has demonstrated effectiveness against pancreatic cancer in laboratory…
- Trial name
- NCT01663272
- Testing
- CABOZANTINIB, gemcitabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan Rogel Cancer Center
Hepatocellular Carcinoma
A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma
This is a pilot single arm study with the primary endpoints of feasibility and preliminary estimates of safety and efficacy. This protocol builds on over 25 years of experience with high dose liver RT (Radiation Therapy), and in…
- Trial name
- NCT02460835
- Testing
- Adaptive Radiation Therapy
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Michigan Rogel Cancer Center
Gastric Cancer, Cancer of Stomach
A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)
This is a Phase 2, signal generating, open-label, 2-Arm, non-randomized study, in patients with metastatic HER2/neu over-expressing gastric cancer or gastroesophageal adenocarcinomas.
- Conditions
- Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma, Stomach Cancer
- Trial name
- nextHERIZON (NCT05311176)
- Testing
- IMU-131, Ramucirumab plus Paclitaxel, Pembrolizumab
- Where
- 7 sites in Australia, Taiwan
- Volunteers
- 7 people
- Sponsor
- Imugene Limited
Gastrointestinal Cancer
Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers
This is an open-label, stratified, two arm design. All patients receive same initial standard preoperative chemotherapy and surgical resection.
- Trial name
- GABLE (NCT03515941)
- Testing
- Oxaliplatin, Capecitabine, Leucovorin
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Tannaz Armaghany
Metastatic Pancreatic Cancer
A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
- Trial name
- BrUOG-PA205 (NCT00439179)
- Testing
- cohort 1, cohort 2, cohort 3
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Brown University
Hepatocellular Carcinoma
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
The purpose of this study is to characterize the baseline variability of a panel of tissue (tumor and adjacent) and blood-based biomarkers obtained from participants with hepatocellular carcinoma (HCC).
- Trial name
- NCT01521780
- Testing
- MRI, Pathology, Blood Samples
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms, Gastrointestinal Tract
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
The study will determine if changes in expression of markers involved in the 5-FU pathways are associated with response to treatment with the combination of lapatinib and capecitabine independent of tumor erbB2 status.
- Trial name
- NCT00526669
- Testing
- Lapatinib and Capecitabine
- Where
- 22 sites in United States, Canada and 4 more
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Hepatocellular Carcinoma, Hepatoma
Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
This study will combine two therapies to treat patients with unresectable hepatocellular carcinoma; sorafenib, and drug eluting beads delivered intra-arterially.
- Trial name
- NCT00844883
- Testing
- sorafenib, LC Bead-TACE
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Gastric Cancer
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
The main objective of the Phase 2 part of the study is to evaluate the efficacy of bemarituzumab (FPA144), a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in…
- Trial name
- FIGHT (NCT03694522)
- Testing
- Bemarituzumab, Modified FOLFOX6
- Where
- 189 sites in United States, Australia and 16 more
- Volunteers
- 155 people
- Sponsor
- Five Prime Therapeutics, Inc.
Solid Cancer
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed.
- Trial name
- NCT03890731
- Testing
- BAY73-4506 (Regorafenib, Stivarga)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 6 people
- Sponsor
- Bayer
Crohn's Disease
Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 [NCT00308581].
- Trial name
- Welcome2 (NCT00333788)
- Testing
- Certolizumab pegol (CDP870)
- Where
- 65 sites in United States, Austria and 10 more
- Volunteers
- 233 people
- Sponsor
- UCB Pharma
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to kill tumor cells or stop them from growing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that…
- Trial name
- NCT01189227
- Testing
- Postoperative chemotherapy, Perioperative chemotherapy
- Where
- 283 sites in United States
- Volunteers
- 9 people
- Sponsor
- NSABP Foundation Inc
Cirrhosis, End Stage Liver Disease
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies).
- Conditions
- Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications
- Trial name
- MHALT (NCT03534141)
- Testing
- Esophageal cooling/warming device, Mild hypothermia, Normothermia
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of California, San Francisco
Liver Cancer
Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
The most frequently used products in CHE are doxorubicin (36%), cisplatin (31%), and epirubicin (12%). But until recently, there were no obvious reasons to use one product over another.
- Trial name
- IDASPHERE II (NCT02185768)
- Testing
- idarubicin, Dc- Beads 300-500µm
- Where
- 7 sites in France
- Volunteers
- 46 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colo-rectal Cancer
Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC
The aim of this 2-year study will assess the acceptability and feasibility of offering Problem Solving Skills Therapy (PSST) to cancer survivors and their caregivers focusing on the highest risk patients with distress.
- Trial name
- NCT03567850
- Testing
- Problem solving Skills Training
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Roswell Park Cancer Institute
Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
This phase II trial studies how well ramucirumab works in treating patients with previously treated biliary cancers that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced)…
- Conditions
- Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Stage III Gallbladder Cancer AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7
- Trial name
- NCT02520141
- Testing
- Laboratory Biomarker Analysis, Ramucirumab
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.